Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

$8.3Bn Coronavirus Response Act Lays Out US FDA’s, CDC’s And Localities’ Roles In Fighting Virus

Executive Summary

An $8.3bn “Coronavirus Preparedness and Response Supplemental” funding act approved by the US Congress last week and signed into law on 6 March provides dollars and lays out the roles federal agencies, such as the FDA, and state and local agencies must play in containing and controlling the spread of COVID-19.

You may also be interested in...



US COVID-19 Testing Costs Covered By 2nd Coronavirus Response Act; Third $1Tn Relief Bill Coming

The US Congress wrapped up work on 18 March on a second COVID-19 preparedness bill to cover costs of testing uninsured individuals, military beneficiaries and other outbreak responses. A planned third COVID-19 relief package would dole out $1tn to agencies and device makers.

COVID-19 Fact File: Global Diagnostic Test Pipeline

Medtech Insight is tracking the IVD companies manufacturing tests for SARS-CoV-2, the coronavirus that causes COVID-19.

US Hospitals Cancel Elective Surgeries, Team Up With Medtechs To Find Remote-Monitoring Solutions

US health systems are canceling elective surgeries in response to COVID-19 to preserve critical resources. Massachusetts General Hospital works with medtechs to find technological solutions to keep patients and caregivers safe.

Related Content

Topics

UsernamePublicRestriction

Register

MT126368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel